Autologous Stem Cell Transplantation Outcomes in Patients With Peripheral T-Cell Lymphomas
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Non-Hodgkin Lymphoma
Patients With NHL More Likely to Die of Cardiovascular Disease Compared With General Population
In this retrospective study, age-specific risk of death from cardiovascular disease was 14-fold higher in patients with NHL compared with the general population.
A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL
Checkpoint-based therapies may sensitize patients to subsequent therapies.
The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
[Cancer Management and Research] Researchers sought to determine the effect of intravenous hydration on plasma methotrexate clearance on pediatric oncology patients receiving HD-MTX for ALL, NHL, or osteosarcoma.
FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications
FDA approval was based on results of the single-arm phase 2 JULIET clinical trial.
Durable Tumor Response Seen in Some Lymphomas With Tazemetostat
Tazemetostat demonstrated preclinical activity against EZH2-mutant non-Hodgkin lymphomas.
PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma
The ability to make early adjustments to treatment has the potential to improve survival.
Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.
